A Novel Mutation (Lys31Arg) in the DMD Gene Impacts on Neuromuscular Dysfunctions Found by Whole Exome Sequencing and In Silico Analyses in an Iranian Family


Cite item

Full Text

Abstract

Background:Duchene Muscular Disorder (DMD) is a severe X-linked recessive neuromuscular disease. Previous reports predicted that one-third of cases with a fatal X-linked recessive disease will be caused by a novel mutation, and the mutation rate for DMD seems to be higher in males.

Objective:A novel mutation in the DMD gene DMD (NM_004006.3):c.92A>G (p.Lys31Arg) is suggested for males because of their heterozygous mothers carrying the mutant alleles

Method:Whole Exome Sequencing (WES) was done for a 25-year-old female followed by the screening of the novel mutation in her parents and her brother by the Sanger sequencing technique. Some in silico analyses were run to find the putative alterations in wild-type and mutant structures by PolyPhen-2 and Mupro. Notably, SWISS-MODEL was performed to build a reliable model for the mutant allele based on the PDB ID: 1DXX structure. Also, superimposition was done by PyMol.

Results:WES analysis revealed three novel mutations including DLD (exon13:c.G1382A:p. G461E), ABCA3 (exon12:c.G1404C:p.W468C), and DMD (exon2:c.A92G:p.K31R) in the case. Focusing on DMD mutation, Sanger sequencing of the patient’s parents and brother indicated no mutant allele in her mother and brother but a mutant allele in her father as a hemizygous pattern. In silico analyses showed no considerable change regarding pathogenic impact.

Conclusion:In conclusion, our findings revealed no pathogenic effect of the new mutation (K31R) of the DMD gene in an Iranian 25-year-old woman. Because of the DMD importance in preclinical diagnosis, these data may shed a light on the diagnosis of this mutation in future pregnancies.

About the authors

Vahid Omarmeli

, Dr. Shaveisi-zadeh Medical Genetic Lab

Email: info@benthamscience.net

Kai-Uwe Lewandrowski

, Center for Advanced Spinal Surgery of Southern Arizona

Email: info@benthamscience.net

Marjan Assefi

Department of Biology, University of North Carolina

Email: info@benthamscience.net

Hanieh Faizmahdavi

Department of Obstetrics and Gynecology, Clinical Research Development Center, Imam Reza hospital,, Kermanshah University of Medical Sciences

Email: info@benthamscience.net

Alireza Sharafshah

, Dr. Shaveisi-zadeh Medical Genetic Lab

Email: info@benthamscience.net

Nasrin Mansouri

Department of Obstetrics and Gynecology, Clinical Research Development Center, Imam Reza Hospital,, Kermanshah University of Medical Sciences

Author for correspondence.
Email: info@benthamscience.net

References

  1. Chung J, Smith AL, Hughes SC, et al. Twenty‐year follow‐up of newborn screening for patients with muscular dystrophy. Muscle Nerve 2016; 53(4): 570-8. doi: 10.1002/mus.24880 PMID: 26260293
  2. Hoffman EP, Brown RH Jr, Kunkel LM. Dystrophin: The protein product of the duchenne muscular dystrophy locus. Cell 1987; 51(6): 919-28. doi: 10.1016/0092-8674(87)90579-4 PMID: 3319190
  3. Pane M, Scalise R, Berardinelli A, et al. Early neurodevelopmental assessment in Duchenne muscular dystrophy. Neuromuscul Disord 2013; 23(6): 451-5. doi: 10.1016/j.nmd.2013.02.012 PMID: 23535446
  4. Ferlini A, Neri M, Gualandi F. The medical genetics of dystrophinopathies: Molecular genetic diagnosis and its impact on clinical practice. Neuromuscul Disord 2013; 23(1): 4-14. doi: 10.1016/j.nmd.2012.09.002 PMID: 23116935
  5. Findlay AR, Wein N, Kaminoh Y, et al. Clinical phenotypes as predictors of the outcome of skipping aroundDMD exon 45. Ann Neurol 2015; 77(4): 668-74. doi: 10.1002/ana.24365 PMID: 25612243
  6. Ogura Y, Tajrishi MM, Sato S, Hindi SM, Kumar A. Therapeutic potential of matrix metalloproteinases in Duchenne muscular dystrophy. Front Cell Dev Biol 2014; 2: 11. doi: 10.3389/fcell.2014.00011 PMID: 25364719
  7. Cirak S, Arechavala-Gomeza V, Guglieri M, et al. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: An open-label, phase 2, dose-escalation study. Lancet 2011; 378(9791): 595-605. doi: 10.1016/S0140-6736(11)60756-3 PMID: 21784508
  8. Haldane JBS. The rate of spontaneous mutation of a human gene. J Genet 1935; 31(3): 317-26. doi: 10.1007/BF02982403 PMID: 15689625
  9. Haldane BJBS. Mutation in the sex-linked recessive type of muscular dystrophy; a possible sex difference. Ann Hum Genet 1956; 20(4): 344-7. doi: 10.1111/j.1469-1809.1955.tb01289.x PMID: 13314403
  10. Prior TW, Papp AC, Snyder PJ, et al. A missense mutation in the dystrophin gene in a Duchenne muscular dystrophy patient. Nat Genet 1993; 4(4): 357-60. doi: 10.1038/ng0893-357 PMID: 8401582
  11. Prior TW, Bartolo C, Papp AC, et al. Identification of a missense mutation, single base deletion and a polymorphism in the dystrophin exon 16. Hum Mol Genet 1994; 3(7): 1173-4. doi: 10.1093/hmg/3.7.1173 PMID: 7981690
  12. Saad FA, Vita G, Toffolatti L, Danieli GA. A possible missense mutation detected in the dystrophin gene by double strand conformation analysis (DSCA). Neuromuscul Disord 1994; 4(4): 335-41. doi: 10.1016/0960-8966(94)90069-8 PMID: 7981590
  13. Goldberg LR, Hausmanowa-Petrusewicz I, Fidzianska A, Duggan DJ, Steinberg LS, Hoffman EP. A dystrophin missense mutation showing persistence of dystrophin and dystrophin‐associated proteins yet a severe phenotype. Ann Neurol 1998; 44(6): 971-6. doi: 10.1002/ana.410440619 PMID: 9851445

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2024 Bentham Science Publishers